Last reviewed · How we verify
PCSK9 inhibitor plus statin
At a glance
| Generic name | PCSK9 inhibitor plus statin |
|---|---|
| Also known as | alirocumab |
| Sponsor | Beijing Anzhen Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
- Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (PHASE3)
- Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke (PHASE2, PHASE3)
- DNV001 Injection in Patients With Hypercholesterolemia (PHASE2)
- Very Early PCSK9 Inhibition for Acute Myocardial Infarction (NA)
- A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. (PHASE4)
- INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2) (NA)
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PCSK9 inhibitor plus statin CI brief — competitive landscape report
- PCSK9 inhibitor plus statin updates RSS · CI watch RSS
- Beijing Anzhen Hospital portfolio CI